Loading
Pralsetinib, a second selective RET inhibitor, shrank tumours in 61 percent of previously treated and 70 percent of untreated patients with RET fusion-positive lung cancer, giving an alternative to selpercatinib.
Phase 1/2 study including 233 patients with RET fusion-positive non-small-cell lung cancer treated with pralsetinib 400 mg daily.
Objective response was 61 percent in patients previously treated with platinum chemotherapy and 70 percent in treatment-naive patients, with median duration of response not reached in the latter; neutropenia, hypertension and liver enzyme rise were common.
Pralsetinib is approved for RET fusion-positive lung cancer and is used where selpercatinib is unavailable or not tolerated.
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.